Javascript must be enabled to continue!
The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia
View through CrossRef
AbstractUsing immunohistochemistry, we investigated the expression of c-mpl in bone marrow megakaryocytes of 88 patients with essential thrombocythemia (ET), 6 patients with secondary thrombocytosis (ST), and 20 patients with lymphoma (controls). Considering both the pattern of expression and the staining intensity, we identified a uniform and a heterogeneous pattern of c-mplexpression. The uniform pattern was found in all the controls, all the patients with ST, and 28 of the patients with ET, with a strong staining intensity observed in most megakaryocytes (> 80%). In contrast, c-mpl expression was heterogeneous in 60 patients with ET, 18 of whom (30%) presented with thrombosis at diagnosis, a significant difference from patients with a uniform c-mpl pattern (2 of 28; 7%; P = .026). In particular, the overrepresentation of thrombotic complications in patients with a heterogeneous c-mpl expression pattern was found mainly among patients with a significant percentage (10% to 40%) of weakly stained or c-mpl–negative megakaryocytes (heterogeneous-weak pattern; 13 of 30; 43%;P = .002). Accordingly, this pattern was associated with a 6.1-fold increased risk of thrombosis compared with that of patients with a uniform c-mpl pattern. In conclusion, the presence of a heterogeneous pattern of c-mpl distribution in bone marrow megakaryocytes could be a useful diagnostic criterion in the differential diagnosis of thrombocytosis. Furthermore, detection of a significant percentage of weakly stained or c-mpl–negative megakaryocytes can identify patients with a higher risk of thrombosis.
Title: The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia
Description:
AbstractUsing immunohistochemistry, we investigated the expression of c-mpl in bone marrow megakaryocytes of 88 patients with essential thrombocythemia (ET), 6 patients with secondary thrombocytosis (ST), and 20 patients with lymphoma (controls).
Considering both the pattern of expression and the staining intensity, we identified a uniform and a heterogeneous pattern of c-mplexpression.
The uniform pattern was found in all the controls, all the patients with ST, and 28 of the patients with ET, with a strong staining intensity observed in most megakaryocytes (> 80%).
In contrast, c-mpl expression was heterogeneous in 60 patients with ET, 18 of whom (30%) presented with thrombosis at diagnosis, a significant difference from patients with a uniform c-mpl pattern (2 of 28; 7%; P = .
026).
In particular, the overrepresentation of thrombotic complications in patients with a heterogeneous c-mpl expression pattern was found mainly among patients with a significant percentage (10% to 40%) of weakly stained or c-mpl–negative megakaryocytes (heterogeneous-weak pattern; 13 of 30; 43%;P = .
002).
Accordingly, this pattern was associated with a 6.
1-fold increased risk of thrombosis compared with that of patients with a uniform c-mpl pattern.
In conclusion, the presence of a heterogeneous pattern of c-mpl distribution in bone marrow megakaryocytes could be a useful diagnostic criterion in the differential diagnosis of thrombocytosis.
Furthermore, detection of a significant percentage of weakly stained or c-mpl–negative megakaryocytes can identify patients with a higher risk of thrombosis.
Related Results
PS1446 THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN JAK2V617F‐POSITIVE MYELOPLROLIFERATIVE NEOPLASMS
PS1446 THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN JAK2V617F‐POSITIVE MYELOPLROLIFERATIVE NEOPLASMS
Background:Constitutive activation of the Jak/Stat signalling pathway is a hallmark of Myeloproliferative Neoplasms (MPN), with 60–90% of patients carrying the activating JAK2 muta...
Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
Introduction: BCR-ABL1-negative myeloproliferative disorders are a sub-group of myeloproliferative neoplasms (MPNs) that consist of polycythemia Vera (PV), Essential thrombocythemi...
Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl
Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl
Mice with a null mutation in the thrombopoietin (TPO) receptor c-Mpl were generated by gene targeting. c-mpl-deficient mice developed normally but were deficient in megakaryocytes ...
PDPN/CLEC-2 axis modulates megakaryocyte subtypes in a hematopoietic stem cell-regulating megakaryocyte-dominant manner
PDPN/CLEC-2 axis modulates megakaryocyte subtypes in a hematopoietic stem cell-regulating megakaryocyte-dominant manner
Abstract
Introduction
Megakaryocytes are classified into several subtypes including LSP1-positive immune-skewed, MYLK4-positive...
Pengaruh Keahlian Brand Ambassador RRQ pada Minat Menonton
Pengaruh Keahlian Brand Ambassador RRQ pada Minat Menonton
Abstract. The Indonesian e-sports industry has experienced rapid growth, particularly through the Mobile Legends Professional League Indonesia (MPL ID), which attracts millions of ...
Lipid Composition and Lipid Synthesis in Guinea Pig Megakaryocytes and Platelets
Lipid Composition and Lipid Synthesis in Guinea Pig Megakaryocytes and Platelets
Lipid composition and lipid synthesis have been compared in guinea pig megakaryocytes and platelets. Megakaryocytes were isolated from guinea pigs to 85% purity. Lipids were extrac...
Bernard‐Soulier syndrome: quantitative characterization of megakaryocytes and platelets by flow cytometric and platelet kinetic measurements
Bernard‐Soulier syndrome: quantitative characterization of megakaryocytes and platelets by flow cytometric and platelet kinetic measurements
Abstract: Platelets and megakaryocytes have been characterized in a Bernard‐Soulier syndrome (BSS) kindred with respect to glycoprotein (GP) membrane receptors and measurements of...
Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
Abstract
Background: Thrombocytopenia is a common complication in cancer patients undergoing chemotherapy. Chemotherapy-induced thrombocytopenia (CIT) leads to dose reducti...

